Sugi Predict

Sugi Predict / Compounds / SCHEMBL18619675

SCHEMBL18619675

SCHEMBL18619675

C=CC(=O)N1CC[C@@H](Nc2ncnc(N)c2C(=N)C(=O)O)C1

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 7/20 0.61
▸ EGFR P00533 1/20 0.54
▸ JAK3 P52333 13/20 0.53
▸ JAK1 P23458 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18619676 1.00 BTK (0.61) BTKEGFRJAK3JAK1
SCHEMBL18618516 0.95 BTK (0.67) BTKEGFRJAK3JAK1
SCHEMBL18599148 0.88 BTK (0.59) BTKEGFRJAK3JAK1
SCHEMBL21899554 0.84 BTK (0.67) BTKEGFRJAK3JAK1
SCHEMBL17816357 0.81 BTK (0.77) BTKEGFR
SCHEMBL21929547 0.80 BTK (0.66) BTKEGFRJAK3JAK1
SCHEMBL14228143 0.78 BTK (0.86) BTKEGFRJAK3JAK1
SCHEMBL18877721 0.78 BTK (0.86) BTKEGFRJAK3JAK1
SCHEMBL21386782 0.78 BTK (0.67) BTKEGFR
SCHEMBL19533468 0.78 JAK3 (0.68) BTKEGFRJAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
US-20200061067-A1 AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 — — US disclosed
US-10329300-B2 Pyrazolo[3,4-d]pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2019-06-25 — — US disclosed
US-20180201615-A1 PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO. , LTD. (JP) 2018-07-19 — — US disclosed
US-20180201615-A1 PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO. , LTD. (JP) 2018-07-19 — — US disclosed
WO-2017038838-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX BTK 2964/4885EGFR 2082/4885JAK3 196/4885
US-20180201615-A1 PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF ERBB2, JAK2, ERBB4 BTK 136/4885EGFR 5/4885JAK3 15/4885
US-10329300-B2 Pyrazolo[3,4-d]pyrimidine compound or salt thereof ERBB2, JAK2, ERBB4 BTK 136/4885EGFR 5/4885JAK3 15/4885
US-20200061067-A1 AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND ZYX, DPYD, ZFX BTK 2964/4885EGFR 2082/4885JAK3 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.